FortressBiotech優先A FBIOP 深 滬
已收盤 05-08 16:00:00 美东时间
13.501
+0.011
+0.08%
華盛通- 最 高13.64
- 今 開13.26
- 成交量 2.91万股
- 最 低 13.26
- 昨 收 13.49
- 總市值 4626.98万
- 52周最高 14.64
- 市盈率 靜 --
- 換手率 0.85%
- 52周最低 6.27
- 委 比 -53.88%
- 總股本 342.71万
- 歷史最高 20.5506
- 量 比 2.21
- 振 幅 2.82%
- 歷史最低 -1.5766
- 每 手 1
- 風險率 2.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fortress Biotech Q4 EPS $(0.30) Beats $(0.42) Estimate, Sales $16.079M Miss $21.018M Estimate
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.42) by 28.57 percent. This is a 15.38 percent decrease over losses of $(0.26) per share from
04-01 05:19
Fortress Biotech And Cyprium Therapeutics Announce The Closing Of The Sale Of Cyprium's Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $205M
Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing of the sale of Cyprium's Rare Pediatric Disease Priority Review
03-31 04:17
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech and its subsidiary Cyprium Therapeutics announce the sale of Cyprium’s Rare Pediatric Disease Priority Review Voucher for $205 million. Fortress, as the majority shareholder, expects to receive over $100 million, enhancing its financial flexibility. The transaction follows three FDA approvals in the past 15 months and the sale of Checkpoint Therapeutics. Cyprium will continue to earn royalties and milestones from ZYCUBO sales and...
03-30 20:05
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Journey Medical Corporation (Nasdaq: DERM), a pharmaceutical company focused on dermatological treatments, announced on March 18, 2026, that it will release its year-end 2025 financial results after U.S. markets close on March 25, 2026. A conference call and audio webcast will be held on March 25 at 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can join by dialing 1-866-777-2509 (U.S.) or 1-412-317-5413 (interna...
03-18 12:30
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $17 price target.
02-24 00:05
Avenue Therapeutics licenses ATX-04 worldwide for Pompe disease
Avenue Therapeutics licenses ATX-04 worldwide for Pompe disease Avenue Therapeutics, founded by Fortress Biotech Inc., entered into an exclusive worldwide license agreement with Duke University for ATX-04 (clenbuterol) to treat Pompe disease. Avenue said it will advance ATX-04 as an adjunct to enzym
02-23 21:05
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Cyprium Therapeutics已将其罕见儿科疾病优先审评券以2.05亿美元出售，并将部分收益支付给NIH。Sentynl接手ZYCUBO，Cyprium仍享有销售分成和里程碑付款。CEO指出，此交易助力Fortress今年盈利，同时公司在推进基因疗法开发。
02-23 13:30
The top-performing pharma and biotech stocks as group sees resurgence
Pharmaceutical (PJP), (XPH), (PPH) and biotechnology stocks (XBI), (BBH) have officially returned to favor on Wall Street, according to Michael Yee, global head of biotechnology equity research at UBS...
02-14 03:01
Fortress Biotech Announces FDA Approves Its ZYCUBO To Treat Menkes Disease In Pediatric Patients
Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has approved ZYCUBO®
01-13 20:51
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Fortress Biotech and Cyprium Therapeutics announced the FDA approval of ZYCUBO (copper histidinate) for Menkes disease, the first FDA-approved treatment for this rare pediatric condition. Sentynl Therapeutics assumed responsibility for ZYCUBO’s development and commercialization, transferring a Rare Pediatric Disease Priority Review Voucher (PRV) to Cyprium and offering up to $129 million in milestones. ZYCUBO significantly improves survival in Me...
01-13 12:45
